Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Pancreatic Adenocarcinoma
Interventions
DEVICE

Therapeutic procedure combines EUS-Guided Radiofrequency Ablation (RFA)

It will be performed under general anesthesia with intubation, using a sectorial probe echoendoscope to target pancreatic tumors. Prophylactic measures, including intrarectal Diclofenac and antibiotics, are used to prevent complications. A high-frequency monopolar electrode needle is inserted into the lesion under ultrasound guidance, avoiding critical structures like pancreatic and biliary ducts. Energy is delivered until specific safety parameters are met, with multiple applications to maximize tumor coverage. RFA sessions are scheduled before, midway, and after chemotherapy cycles, and progress is monitored with routine imaging. Post-procedure care includes fasting, pain management, and standard blood tests. Patients are typically discharged the day after the procedure if no complications occur. Further treatment plans, including continuation or modification of chemotherapy and RFA, are determined based on disease progression observed in follow-up scans.

All Listed Sponsors
lead

French Society of Digestive Endoscopy

OTHER

NCT06743386 - Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP ) | Biotech Hunter | Biotech Hunter